Tellus Therapeutics Awarded NINDS SBIR Funding for Development of TT-20 for Treatment of Neonatal Brain Injury
DURHAM, NC, UNITED STATES, December 7, 2020 — Tellus Therapeutics today announced the award of a Phase 1 NINDS SBIR grant of $696,000 to fund further preclinical development of TT-20.